Chemodenervation may be considered for selected neurogenic thoracic outlet syndrome patterns involving neck, shoulder, arm, or hand symptoms.
Thoracic outlet syndrome can cause pain, numbness, and weakness in the neck, shoulder, and arm. Dr. Siefferman explains how chemodenervation with botulinum toxin can help relieve pressure on nerves and blood vessels as part of a comprehensive treatment plan.
Our team organizes conditions and treatments into related zones of expertise to make it easier to explore the care paths most relevant to your symptoms and goals.
Use the zone tags above to browse dedicated pages for each focus area, including services, providers, and what to expect during treatment.
Hi, I’m Dr. Jason Siefferman, medical director at Manhattan Pain Medicine. Chemodenervation uses botulinum toxin to weaken and debulk muscles that are interfering with the path of nerves and arteries from inside the thorax to the arm. Specifically with thoracic outlet, the brachial plexus and the nerves and arteries involved are caught up between the muscles either between the anterior middle scalene, between the clavicle and the first rib, and or under the pectoralis minor. And then when the arm is used, it impinges on those structures and causes strangulation of blood flow or nerve function.
We will use botulinum toxin to debulk the muscles so they take up less space and to weaken the muscles so that they don’t actually pull so hard on the structures. This is something that we do every 3 months, and generally the effect builds with each treatment. So we combine this with physical therapy, and generally patients see a very good result.
Chemodenervation for thoracic outlet syndrome is a targeted injection treatment that uses botulinum toxin to temporarily reduce activity in selected muscles that may contribute to nerve compression or irritation in certain neurogenic TOS patterns. It may be considered when scalene, pectoralis minor, or related muscle overactivity appears to contribute to neck, shoulder, chest, arm, hand, numbness, tingling, weakness, or pain symptoms.
At Manhattan Pain Medicine, chemodenervation is not treated as a cure or a universal TOS treatment. It begins with a diagnosis-first evaluation to distinguish neurogenic TOS from vascular TOS, cervical radiculopathy, shoulder pathology, cervical dystonia, peripheral nerve entrapment, and headache-related neck pain.
MPM specialists evaluate whether chemodenervation may be appropriate by first clarifying the type of thoracic outlet syndrome and the likely source of symptoms. TOS can involve nerves, veins, arteries, or conditions that mimic TOS. Patients with arm swelling, discoloration, coldness, loss of pulse, signs of blood clot, or vascular symptoms may need vascular evaluation rather than a pain injection pathway.
When neurogenic TOS is suspected, MPM considers whether scalene, pectoralis minor, or related muscle overactivity may be contributing. Treatment planning depends on diagnosis, exam findings, prior response to therapy, safety factors, and whether injections may support next-step decision-making.
Thoracic outlet syndrome is complex. Symptoms may include neck pain, shoulder pain, chest discomfort, arm pain, hand numbness, tingling, weakness, heaviness, or worsening symptoms with overhead activity. These symptoms can be caused by neurogenic TOS, but they can also come from cervical spine disease, cervical radiculopathy, peripheral nerve entrapment, shoulder pathology, cervical dystonia, headache disorders, or vascular compression.
Chemodenervation may be considered for selected patients with suspected neurogenic TOS when muscle-related compression or irritation appears to be part of the pattern. Botulinum toxin may temporarily reduce activity in muscles such as the scalene or pectoralis minor, potentially reducing symptom burden for some patients. Evidence is mixed, response varies, and benefit is temporary. MPM uses this treatment carefully, often in coordination with physical therapy, vascular surgery, neurology, orthopedics, rehabilitation, or other specialists when appropriate.
Chemodenervation for thoracic outlet syndrome intersects with MPM’s expertise in Complex Chronic Pain and Musculoskeletal issues. Neurogenic TOS may involve pain, numbness, tingling, weakness, muscle overactivity, postural strain, nerve sensitivity, and overlapping neck or headache symptoms. These patterns can become especially complex when patients have already tried physical therapy, medications, activity modification, imaging, nerve studies, or specialist visits without clear relief.
MPM evaluates TOS within this broader clinical context. The team considers whether symptoms are truly consistent with neurogenic TOS, whether vascular symptoms need urgent or specialty evaluation, and whether botulinum toxin treatment may fit safely into the care plan. Treatment may be coordinated with physical therapy, vascular surgery, neurology, orthopedics, rehabilitation, headache care, or other specialists when needed.
Before treatment, MPM reviews the diagnosis, target muscles, injection plan, expected timeline, possible side effects, and safety considerations. During chemodenervation, small amounts of botulinum toxin are injected into selected muscles that may be contributing to neurogenic thoracic outlet symptoms. Depending on the case, this may involve scalene, pectoralis minor, or related muscle targets.
Patients may feel brief pressure, pinching, or soreness during the procedure. The effect is not immediate and may take days to develop. If benefit occurs, it is temporary and may last weeks to months depending on the patient, dose, target, and response. Possible side effects include injection-site pain, bruising, neck weakness, shoulder weakness, swallowing difficulty, voice changes, breathing difficulty, or spread of toxin effect. Follow-up helps determine whether treatment was helpful and what next steps are appropriate.
These guys are the best. I've been going here for over 6 years and their familiarity with my Schwannomatosis (most ppl have never even heard of it - its rather rare) and their ability to diagnose my CRPS quickly and accurately and then treat it like I was merely getting a flu shot is just incredible...
Highly recommended for those who need Pain Management. Everyone at Manhattan Pain Medicine is extremely nice and helpful. I have had very good interactions with both Dr. Siefferman and Dr. Louis. All of the staff is very responsive. 5 stars.
The providers at Manhattan Pain Medicine are exceptional. I wish I had found them 30 years ago!
I genuinely can’t say enough good things about the team at Manhattan Pain Medicine. I have MCAS, EDS, and an inflammatory autoimmune disease, and I’ve basically been searching for answers since I was a kid. I had years of unexplained inflammation markers, chronic pain, and allergic reactions despite...
I have a complex medical history and have seen a lot of doctors over the years. Dr. Mikaberidze and Dr. Siefferman each took the time to really listen and understand everything I had been dealing with. I also appreciated how they work together and communicated about my care. I left with a plan that...
Sharing my gratitude for the pleasant experience last week during my visit, the medical team provided great care and also treated my session as a learning experience, I left my session with a wealth of knowledge. A big thank you to the kind, and professional staff who welcomed me to the office as a...
I cannot say enough good things about Manhattan Pain Medicine. From the moment I walked in, I felt truly cared for and taken seriously. Dr. Nino Mikaberidze, Director of Rheumatology, is exceptional — knowledgeable, compassionate, and incredibly thorough. She takes the time to listen, explains every...
Dr Siefferman is the most thorough, patient doctor I have even been to. Currently I travel from miami to nyc to see him because his bed side manner and desire to help is incomparable.
ZocDoc
This practice is wonderful. I have been a patient of Dr. Siefferman’s since 2019 and he’s extremely helpful and kind. He has brought in a Rheumatologist who is also great. They handle very complex pain issues and always try to find new ways to help me.
Dr. Siefferman is an incredible doctor! He is extremely diligent and knowledgeable. It feels like you are his only patient. He invests a lot of time and effort into your injuries and concerns. I did not find these wonderful qualities with other pain specialists before, who were always rushed and som...
ZocDoc
Dr. Siefferman is a doctor who combines the old world bedside manner of doctors from my childhood (60 years ago) with a sta te of the art embrace of modern technology. It is always a pleasure to have an appointment with him...always has options and solutions to my medical issues. He is truly the doc...
ZocDoc
Dr. Siefferman is a genius. He is very informed and listens attentively.
ZocDoc
Dr. Siefferman and his entire team continue to be efficient, dedicated, and driven by precision and a genuine desire to give fantastic care. Will always recommend.
ZocDoc
Doctor Siefferman is fantastic. Have been seeing him for 5 years. Couldn’t recommend more.
ZocDoc
Dr. Siefferman is the ONLY doctor who has ever been able to diagnose my pain and treat it. He is hands down the best
ZocDoc
Chemodenervation for thoracic outlet syndrome is a targeted injection treatment that uses botulinum toxin to temporarily reduce activity in selected muscles that may contribute to certain neurogenic TOS symptoms. It may be considered when scalene, pectoralis minor, or related muscle overactivity appears to contribute to nerve irritation or compression. It is not a cure for TOS and is not appropriate for every type of TOS. MPM uses a diagnosis-first evaluation before considering treatment.
Botox may help selected patients with suspected neurogenic thoracic outlet syndrome when muscle overactivity contributes to symptoms. It may temporarily reduce activity in muscles such as the scalene or pectoralis minor, which may reduce symptom burden for some patients. Evidence is mixed, and not all patients respond. Botox does not treat every TOS pattern and should not replace physical therapy, vascular evaluation, surgical evaluation, neurologic workup, or other care when needed.
Botulinum toxin is not FDA-approved specifically for thoracic outlet syndrome. Its use for TOS is generally considered off-label and should be approached carefully. Off-label use may still be considered in selected clinical situations, especially suspected neurogenic TOS patterns, but it requires individualized evaluation, discussion of risks and limitations, and realistic expectations. MPM considers whether the patient’s symptoms, diagnosis, safety profile, and care goals support this treatment before recommending injections.
Botulinum toxin injections are most often considered in selected cases of suspected neurogenic thoracic outlet syndrome, where nerve symptoms may be influenced by muscle-related compression or irritation. Neurogenic symptoms may include pain, numbness, tingling, weakness, heaviness, or symptoms worsened by overhead activity. Venous or arterial TOS involves blood vessel compression and may require vascular evaluation. Symptoms such as arm swelling, blue or pale discoloration, coldness, loss of pulse, or signs of blood clot should be evaluated urgently.
Neurogenic thoracic outlet syndrome occurs when nerves traveling through the thoracic outlet region are compressed or irritated. Symptoms may involve neck, shoulder, chest, arm, hand, numbness, tingling, weakness, heaviness, or discomfort with overhead activity. It can be difficult to diagnose because similar symptoms can come from cervical radiculopathy, peripheral nerve entrapment, shoulder conditions, cervical dystonia, or headache-related neck pain. MPM evaluates these possibilities before considering treatment.
Injection sites depend on the patient’s symptom pattern, anatomy, exam findings, and suspected compression source. In selected neurogenic TOS cases, treatment may target the scalene muscles, pectoralis minor, or related muscles that may contribute to compression or irritation. MPM does not select injection sites based only on where pain is felt. The plan is individualized and may use precise anatomical or image-guided techniques depending on the clinical situation.
Scalene or pectoralis minor injections may help selected patients when those muscles appear to contribute to neurogenic TOS symptoms. By temporarily reducing muscle activity, botulinum toxin may reduce compression or irritation for some patients. Response varies, and benefit is temporary. These injections are not appropriate for every patient with neck, shoulder, or arm symptoms. MPM evaluates whether the symptoms fit a neurogenic TOS pattern and whether the target muscles are clinically relevant.
Yes, neurogenic TOS can cause arm or hand numbness, tingling, weakness, heaviness, pain, or symptoms that worsen with overhead activity. However, these symptoms can also come from cervical radiculopathy, peripheral nerve entrapment, shoulder pathology, vascular conditions, or neurologic disease. MPM evaluates the pattern carefully before recommending chemodenervation. New or rapidly worsening weakness, arm discoloration, swelling, coldness, loss of pulse, chest pain, or shortness of breath should be evaluated urgently.
Thoracic outlet syndrome involves compression or irritation in the lower neck and upper chest region where nerves and blood vessels travel toward the arm. Cervical radiculopathy involves irritation or compression of a nerve root in the neck, often from disc or spine-related changes. Both can cause neck, shoulder, arm, hand, numbness, tingling, or weakness. MPM evaluates symptom distribution, exam findings, imaging, nerve studies, and clinical history to help distinguish these conditions before recommending treatment.
Thoracic outlet syndrome involves nerve or blood vessel compression in the thoracic outlet region. Cervical dystonia is a movement disorder involving involuntary neck muscle contractions that can pull or twist the head. Both may cause neck and shoulder symptoms, but they require different treatment planning. Chemodenervation for TOS may target muscles contributing to compression, while chemodenervation for cervical dystonia targets overactive muscles causing abnormal movement. MPM evaluates the pattern before selecting a treatment pathway.
If botulinum toxin injections help TOS symptoms, the effect is temporary and may last weeks to months depending on the patient, target muscles, dose, and response. Some patients may experience limited benefit, while others may have enough relief to support rehabilitation or guide next-step decisions. MPM reassesses symptom response, side effects, function, and duration of benefit before considering whether repeat treatment, further evaluation, or another care pathway is appropriate.
In some cases, injections may have both therapeutic and diagnostic value. Temporary symptom improvement after a targeted injection may support the idea that a specific muscle or region is contributing to symptoms. However, injection response alone does not prove the entire diagnosis, and lack of response does not rule out every TOS pattern. MPM interprets injection response in the context of the full clinical picture, including history, exam findings, prior testing, therapy response, and specialist input.
Surgery or vascular evaluation may be needed when symptoms suggest venous or arterial TOS, blood vessel compression, clotting risk, significant structural compression, progressive neurological issues, or failure of appropriate conservative care. Symptoms such as arm swelling, blue or pale discoloration, coldness of the hand, loss of pulse, sudden severe arm pain, chest pain, shortness of breath, or signs of blood clot require urgent medical evaluation. MPM coordinates care when a vascular, surgical, or neurologic pathway is more appropriate.
Risks may include injection-site pain, bruising, neck weakness, shoulder weakness, temporary swallowing difficulty, voice changes, breathing difficulty, allergic reaction, spread of toxin effect, and condition-specific adverse effects. Extra caution is needed for patients with neuromuscular junction disorders, significant swallowing or breathing problems, active infection at injection sites, pregnancy or breastfeeding considerations, medication interactions, or prior reaction to botulinum toxin. MPM reviews these risks before treatment and evaluates whether the potential benefits justify the procedure.
Before care begins, our team helps patients understand the practical side of treatment, including insurance verification, out-of-network benefits, cost-share estimates, self-pay options, and billing questions. We believe patients should have as much clarity as possible before moving forward.
Chemodenervation for thoracic outlet syndrome is a targeted injection treatment that uses botulinum toxin to temporarily reduce activity in selected muscles that may contribute to neurogenic TOS symptoms. Thoracic outlet syndrome refers to compression or irritation of nerves or blood vessels as they pass through the lower neck, upper chest, and shoulder region toward the arm.
At Manhattan Pain Medicine (MPM), chemodenervation for thoracic outlet syndrome NYC care begins with diagnosis. TOS can be difficult to confirm because many conditions can create similar symptoms. The goal is to determine whether symptoms are consistent with neurogenic TOS, vascular TOS, cervical spine disease, peripheral nerve entrapment, shoulder pathology, cervical dystonia, headache-related neck pain, or another condition.
Thoracic outlet syndrome can involve nerves, veins, or arteries. Neurogenic TOS is the most common category and may cause neck pain, shoulder pain, chest discomfort, arm pain, hand numbness, tingling, weakness, heaviness, or symptoms that worsen with overhead activity. Venous or arterial TOS involves blood vessel compression and may cause arm swelling, discoloration, coldness, loss of pulse, clotting concerns, or sudden severe symptoms.
This distinction is essential. Venous or arterial symptoms require vascular evaluation and may not be appropriate for a pain injection pathway. MPM screens carefully for red flags and coordinates care when vascular, surgical, neurologic, or emergency evaluation is needed.
In selected neurogenic TOS patterns, muscles such as the scalene muscles or pectoralis minor may contribute to compression or irritation around the thoracic outlet. Botulinum toxin may temporarily reduce muscle activity in these areas. For some patients, this may reduce pain, tightness, numbness, tingling, or overhead activity symptoms. It may also help support rehabilitation or clarify whether a specific muscle region is contributing.
Evidence for botulinum toxin in neurogenic TOS is mixed. Some patients may experience temporary relief, while others may not respond. Chemodenervation does not cure TOS, correct anatomy permanently, or replace physical therapy, vascular evaluation, surgical evaluation, neurological workup, imaging, or medication management when those are needed.
Thoracic outlet syndrome can resemble cervical radiculopathy, peripheral nerve entrapment, shoulder pathology, cervical dystonia, and headache-related neck pain. Cervical radiculopathy involves nerve root irritation in the neck and may cause pain, numbness, tingling, or weakness down the arm. Peripheral nerve entrapment may affect specific nerves at the elbow, wrist, or other sites. Shoulder pathology can create pain with overhead activity. Cervical dystonia can cause abnormal neck muscle overactivity and posture changes.
MPM evaluates these overlapping possibilities through history, exam findings, prior imaging, nerve studies, vascular studies, response to therapy, and symptom behavior. This helps determine whether chemodenervation is reasonable or whether another care pathway is more appropriate.
When chemodenervation is considered, MPM identifies the likely muscle targets based on the patient’s symptoms and anatomy. Possible targets may include scalene muscles, pectoralis minor, or related structures when clinically indicated. Injections may be planned using precise anatomical or image-guided techniques depending on the location and safety considerations.
Treatment goals may include temporary symptom reduction, improved tolerance for physical therapy, better overhead function, or support for next-step decision-making. MPM also considers whether the patient should be coordinated with physical therapy, vascular surgery, neurology, orthopedics, rehabilitation, headache care, or a TOS specialist.
Before treatment, MPM reviews the diagnosis, target muscles, safety factors, expected timeline, possible side effects, and follow-up plan. During treatment, small amounts of botulinum toxin are injected into selected muscles. The effect is not immediate and may take days to develop. If benefit occurs, it is temporary and may last weeks to months.
After treatment, MPM tracks changes in pain, numbness, tingling, weakness, overhead activity tolerance, function, and side effects. If injections help, the response may inform future care. If they do not help, MPM may reconsider the diagnosis, recommend further evaluation, or adjust the treatment plan.
Risks may include injection-site pain, bruising, neck weakness, shoulder weakness, swallowing difficulty, voice changes, breathing difficulty, allergic reaction, spread of toxin effect, and condition-specific adverse effects. Extra caution is needed for patients with neuromuscular junction disorders, swallowing or breathing problems, active infection at injection sites, pregnancy or breastfeeding considerations, medication interactions, or prior reaction to botulinum toxin.
Patients should seek urgent evaluation for arm swelling, blue or pale discoloration, coldness of the hand, loss of pulse, sudden severe arm pain, chest pain, shortness of breath, new weakness, new neurological deficits, trouble breathing, trouble swallowing, signs of blood clot, or rapidly worsening symptoms.
For selected patients, chemodenervation may be one useful tool in neurogenic TOS care. MPM’s role is to determine whether the diagnosis, target, safety profile, and care goals support treatment within a broader coordinated plan.
